|
Allele Symbol Allele Name Allele ID |
Tg(EmuSR-tTa)83Bop transgene insertion 83, J Michael Bishop MGI:3040386 |
||||||||||||||||||||||||
| Summary |
5 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• incidence of T cell lymphomas is similar to that in transgenic mice wild-type for Trp53bp2
|
|
• incidence of T cell lymphomas is similar to that in transgenic mice wild-type for Trp53bp2
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 4 to 30% DP thymocytes appear allowing some DN cells to progress to the DP state, which is fewer than in wild-type mice but more than in Rag2 null mice
|
|
• 4 to 30% DP thymocytes appear allowing some DN cells to progress to the DP state, which is fewer than in wild-type mice but more than in Rag2 null mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mutants become moribund without a large peripheral tumor burden, with a median survival of 82 days
|
|
• mutants develop lymphoma, with latency of tumorigenesis reduced compared to single Tg(IghMyc)22Bri/0 mice
• lymphoma-bearing mice treated with doxycycline at the onset of paralysis regain full movement within 2 days of doxycycline treatment, show tumor involution, and live for a further 24-64 days before tumors relapse
|
|
• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver
|
|
• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver
|
|
• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver
|
|
• partial hind leg paralysis is seen in some mutants, most likely attributed to lymphoma
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice die within a mean latency of 4 weeks when dox is removed at the newborn stage
|
|
• embryonic lethality is seen in the absence of doxycycline (dox)
|
|
• splenomegaly in mice when dox is removed in newborns
|
|
• generalized lymphadenopathy in mice when dox is removed in newborns
|
|
• mice are growth retarded when dox is removed in newborns
|
|
• splenomegaly in mice when dox is removed in newborns
|
|
• splenomegaly in mice when dox is removed in newborns
|
|
• induction of transgene expression by removal of dox in newborns results in the development of a skin disease affecting the snout and paws, first detectable at 3 weeks of age
|
|
• lymphomatous infiltration is sometimes seen in the dermis below the keratoacanthoma-like lesions
|
|
• mice exhibit skin nodules of a hyperplasia of the epidermis when dox is removed at the newborn stage, suggesting a keratoacanathoma-like lesion
• mice that are moribund with tumors and treated with dox for 12 days to suppress transgene expression exhibit a clearing of skin lesions and regrowth of hair within 3 weeks
• treatment of mice with an ALK phosphorylation inhibitor PF-2341066 results in a progressive clearing of skin lesions
|
|
• mice develop aggressive lymphoma/leukemia when dox is removed in newborns
• lymphoma/leukemia are derived from B cells
|
|
• mice develop aggressive lymphoma/leukemia when dox is removed in newborns
• lymphoma/leukemia are derived from B cells
• transplantation of mutant bone marrow into recipient mice results in the development of B-cell lymphoma without skin lesions
• mice that are moribund with tumors and treated with dox for 12 days exhibit tumor regression
• treatment of mice with an ALK phosphorylation inhibitor PF-2341066 results in tumor regression
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| non-Hodgkin lymphoma | DOID:0060060 |
OMIM:605027 |
J:160236 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice die within a mean latency of 4 weeks when dox is removed at the newborn stage
|
|
• embryonic lethality is seen in the absence of doxycycline (dox)
|
|
• splenomegaly in mice when dox is removed in newborns
|
|
• induction of transgene expression by removal of dox in newborns results in the development of a skin disease affecting the snout and paws, first detectable at 3 weeks of age
|
|
• lymphomatous infiltration is sometimes seen in the dermis below the keratoacanthoma-like lesions
|
|
• mice exhibit skin nodules of a hyperplasia of the epidermis when dox is removed at the newborn stage, suggesting a keratoacanathoma-like lesion
• mice that are moribund with tumors and treated with dox for 12 days to suppress transgene expression exhibit a clearing of skin lesions and regrowth of hair within 3 weeks
|
|
• splenomegaly in mice when dox is removed in newborns
|
|
• generalized lymphadenopathy in mice when dox is removed in newborns
|
|
• mice develop aggressive lymphoma/leukemia when dox is removed in newborns
• lymphoma/leukemia are derived from B cells
|
|
• mice develop aggressive lymphoma/leukemia when dox is removed in newborns
• lymphoma/leukemia are derived from B cells
• transplantation of mutant bone marrow into recipient mice results in the development of B-cell lymphoma without skin lesions
• mice that are moribund with tumors and treated with dox for 12 days exhibit tumor regression
|
|
• splenomegaly in mice when dox is removed in newborns
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| non-Hodgkin lymphoma | DOID:0060060 |
OMIM:605027 |
J:160236 | |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/16/2024 MGI 6.23 |
|
|
|
||
Analysis Tools